| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00228-003-0567-5 |
| P698 | PubMed publication ID | 12698307 |
| P50 | author | Christian Funck-Brentano | Q43249091 |
| P2093 | author name string | Elke Schaeffeler | |
| Ulrich Brinkmann | |||
| Reinhold Kerb | |||
| Céline Verstuyft | |||
| Patrice Jaillon | |||
| Laurent Becquemont | |||
| Mathias Schwab | |||
| P2860 | cites work | Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition | Q44289525 |
| Effect of grapefruit juice on digoxin pharmacokinetics in humans. | Q53883936 | ||
| MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects | Q77133730 | ||
| Modulation by dietary salt of verapamil disposition in humans | Q77677356 | ||
| Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene | Q78500959 | ||
| Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. | Q34140197 | ||
| Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo | Q35113118 | ||
| MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine | Q35803858 | ||
| Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers | Q36053724 | ||
| Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine | Q40753067 | ||
| Identification of functionally variant MDR1 alleles among European Americans and African Americans | Q43705904 | ||
| Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study | Q43865209 | ||
| Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. | Q44110147 | ||
| P433 | issue | 12 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 809-812 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Digoxin pharmacokinetics and MDR1 genetic polymorphisms | |
| P478 | volume | 58 |
| Q35914690 | A case for pharmacogenomics in management of cardiac arrhythmias. |
| Q39531115 | ABCB1 and SLCO1B3 Gene Polymorphisms and Their Impact on Digoxin Pharmacokinetics in Atrial Fibrillation Patients among the Tunisian Population |
| Q41152619 | ABCB1 gene variants, digoxin and risk of sudden cardiac death in a general population |
| Q36592129 | ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. |
| Q37575649 | ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs |
| Q39145949 | An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure |
| Q26849254 | Clinical application of cardiovascular pharmacogenetics |
| Q35778961 | Clinical pharmacology: special safety considerations in drug development and pharmacovigilance |
| Q97905256 | Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin |
| Q43791088 | Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? |
| Q43055993 | Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren |
| Q46816943 | Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients |
| Q45939354 | Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. |
| Q36597641 | Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics |
| Q37705351 | Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation |
| Q21560761 | Gene-wide characterization of common quantitative trait loci for ABCB1 mRNA expression in normal liver tissues in the Chinese population |
| Q58766132 | Improvement of Adequate Digoxin Dosage: An Application of Machine Learning Approach |
| Q37811970 | In Vivo Probes of Drug Transport: Commonly Used Probe Drugs to Assess Function of Intestinal P-glycoprotein (ABCB1) in Humans |
| Q43244739 | Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects |
| Q42246055 | Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects |
| Q46542210 | Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin |
| Q79761642 | Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex |
| Q48159998 | Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania |
| Q39204093 | Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters |
| Q33905302 | MDR1 Ala893 polymorphism is associated with inflammatory bowel disease |
| Q36417994 | MDR1 gene polymorphisms and clinical relevance |
| Q36120816 | Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. |
| Q36659167 | Membrane transporter proteins: a challenge for CNS drug development. |
| Q35071734 | Meta-Analysis of ABCB1 3435C>T Polymorphism and Colorectal Cancer |
| Q35827187 | Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression |
| Q36024688 | Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients |
| Q35968259 | Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters |
| Q34538009 | Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis |
| Q47949113 | P-glycoprotein function in the elderly |
| Q81344064 | P-glycoprotein polymorphism in hypo- and hyper-thyroidism patients |
| Q37811964 | P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations |
| Q26852239 | Pharmacogenetics in chronic heart failure: new developments and current challenges |
| Q36084069 | Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update |
| Q35873680 | Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity |
| Q38242601 | Pharmacogenetics of membrane transporters: a review of current approaches. |
| Q37641869 | Pharmacogenetics of membrane transporters: an update on current approaches |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q38983589 | Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. |
| Q36326202 | Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q34327594 | Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies |
| Q38998634 | Pharmacogenomics of heart failure: a systematic review |
| Q37550561 | Pharmacokinetics in special populations |
| Q48391405 | Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients |
| Q38896107 | Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics |
| Q47822510 | Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. |
| Q42751321 | Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users |
| Q34400733 | Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver |
| Q44653786 | Rifampicin reduces plasma concentrations of celiprolol |
| Q36349672 | Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition |
| Q33653498 | The Genetic Challenges and Opportunities in Advanced Heart Failure |
| Q43257503 | The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes |
| Q37735146 | Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy |
| Q33714593 | Xenobiotic, bile acid, and cholesterol transporters: function and regulation. |
Search more.